 |
BioWorld-International-2007-07-18
Arpida Gains On Iclaprim Data From Second cSSSI Pivotal Trial
Arpida Gains On Iclaprim Data From Second cSSSI Pivotal Trial
Arpida AG remains on track to file for marketing approval for the intravenous antibiotic iclaprim in the U.S. and Europe before the year-end, following positive topline data from a second pivotal trial of the compound in patients with complicated skin and skin structure infection (cSSSI). (BioWorld International)